Over 40 generic drug makers are set to launch their cheaper versions of Novo Nordisk’s diabetes and obesity drugs Ozempic and Wegovy in India, starting today. Many big-name generics companies, including Sun Pharma, Dr. Reddy’s, Cipla, Biocon, and Mankind, are expected to join the fray.
One company has announced it will sell its product for just 1,290 rupees ($13.79) per month, a fraction of Novo Nordisk’s prices ranging from 8,800 rupees ($94) to 16,400 rupees ($175). With so many options available, experts warn that this could lead to misuse, poor titration, and unmanaged side effects.
The Indian market for diabetes medication is massive, with an estimated 90 million people living with the condition. As the patent on semaglutide expires, India will be a key test case for generic competition from around the world. However, experts caution that the competitive landscape may change significantly by the time Europe and the US follow suit in 2031-32.
As more companies enter the market, there is growing concern about device quality and aggressive marketing tactics, which could overwhelm prescribers. The next few weeks are expected to be chaotic as generic versions flood the market, potentially leading to a range of unintended consequences.
Source: https://www.fiercepharma.com/pharma/novos-semaglutide-losing-patent-protection-indian-drugmakers-set-launch-their-generics